Stock Groups

Biomarin Pharma Earnings Beat, Revenue Misses In Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Biomarin Pharma Earnings Beat, Income Misses In Q3

Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday third quarter that beat analysts’ forecasts and income that fell in need of expectations.

Biomarin Pharma introduced earnings per share of $-0.2 on income of $408.7M. Analysts polled by Investing.com anticipated EPS of $-0.2427 on income of $435.89M.

Biomarin Pharma shares are down 18.21% from the start of the 12 months, nonetheless down 22.51% from its 52 week excessive of $92.55 set on December 17, 2020. They’re under-performing the Nasdaq which is up 18.21% from the beginning of the 12 months.

Biomarin Pharma shares misplaced 0.31% in after-hours commerce following the report.

Biomarin Pharma follows different main Healthcare sector earnings this month

Biomarin Pharma’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on income of $23.34B, in comparison with forecasts EPS of $2.35 on income of $23.64B.

Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on income of $9.33B, in comparison with forecast for EPS of $4.68 on income of $8.33B.

Keep up-to-date on the entire upcoming earnings studies by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media wish to remind you that the information contained on this web site will not be essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs are usually not offered by exchanges however reasonably by market makers, and so costs might not be correct and will differ from the precise market worth, which means costs are indicative and never acceptable for buying and selling functions. Subsequently Fusion Media doesn`t bear any duty for any buying and selling losses you may incur because of utilizing this knowledge.

Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or injury because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding types attainable.



[ad_2]